Clinical Trials Browser

Recruiting × Urinary Bladder Neoplasms × Docetaxel × Clear all

Urinary Bladder Neoplasms

NCT07322263 2026-04-17

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

Phase 2 Recruiting

174 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT03317158 2026-04-15

ADAPT-BLADDER

Phase 1/2 Recruiting

55 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06704191 2026-03-30

In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial

Phase 1/2 Recruiting

40 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06488222 2026-03-11

Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer

Phase 2 Recruiting

34 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT05644041 2026-02-27

Intravesical Gem/Doce in Patients With NMIBC

Phase 2 Recruiting

25 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT05024734 2025-03-11

GAIN INST

Phase 2 Recruiting

34 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT06732531 2025-01-09

Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer

Phase 1/2 Recruiting

48 enrolled

Genitourinary

Urinary Bladder Neoplasms

Clinical Trials

TroFuse-031

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

ADAPT-BLADDER

In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial

Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer

Intravesical Gem/Doce in Patients With NMIBC

GAIN INST

Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer